#Incretin mimetics
GLP-1, GIP, glucagon receptor agonists.
SURPASS-CVOT Beyond MACE
A 2026 commentary argues that SURPASS-CVOT may require endpoints beyond MACE, but its biological framework remains a hypothesis, not new trial evidence.
GLP-1 drugs in schizophrenia: 7 trials
Seven randomized trials suggest GLP-1 drugs, including semaglutide, can reduce antipsychotic-associated metabolic harm.
GLP-1 addiction study has no results yet
A planned semaglutide study will track addiction and social outcomes in 1,200 people, but it has no participant results or public protocol yet.
GLP-1 Hair Loss Review: What It Found
A 2026 GLP-1 hair loss review links shedding mainly to weight change, but the narrative evidence cannot prove direct drug causation.
GLP-1 Drugs and Spine Surgery Outcomes
A 23-study systematic review found procedure-specific, mostly observational associations rather than a clear benefit or harm in spine surgery.
GLP-1 Drugs and Substance Use Evidence
A 2026 review maps early semaglutide, exenatide, alcohol and tobacco findings without establishing incretin drugs as addiction treatments.
GLP-1 Drugs Cut Test-Meal Intake
A 2026 meta-analysis found GLP-1 therapy reduced intake by about 271 kcal at one test lunch, with real-world diet effects still uncertain.
Pediatric Obesity Drug Review: Gaps
A 2026 pediatric obesity drug review links adolescent semaglutide evidence with adult retatrutide research while leaving long-term safety open.
Adolescent GLP-1 Review: Evidence Gaps
A 2026 review finds short-term benefits from adolescent GLP-1 therapy but major gaps around growth, puberty, cognition and lifelong effects.
Personalising Tirzepatide Maintenance
A Lancet letter raises the maintenance question. SURMOUNT-MAINTAIN supports continued tirzepatide but does not supply an individual dosing formula.
Semaglutide equity model explained
A 25-year semaglutide model weighed cost per QALY against projected equity for older adults with obesity and cardiovascular disease.
Tirzepatide Ocular Study: What We Know
A letter on tirzepatide ocular outcomes has no public abstract. The underlying cohort found associations, not proof of eye protection.